‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences
As technology increasingly helps find drug targets, enhance the diagnosis of diseases, speed up the testing of new therapeutics and essentially angle its way into every corner of life sciences, entrepreneurs will need a new type of VC firm.
At least, that’s the thinking behind the latest fund to drop. Dimension, out of New York and San Francisco, launched Wednesday with $350 million to bankroll a couple dozen startups, some of which it will help form. The portfolio already includes Kaleidoscope, maker of a tool to help teams keep tabs on R&D, and Enveda Biosciences, which is nearing the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.